Vimarsana
Biggest News Aggregation in the World

Page 2 - Topline Phase News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Topline Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Topline Phase Today - Breaking & Trending Today

I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates - Vimarsana News

I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates

Significant progress made year-to-date on key clinical assets: ‐ Uliledlimab (CD73 antibody): Encouraging early results were presented at ASCO 2023 ‐...

Vaxcyte Reports Second Quarter 2023 Financial Results and - Vimarsana News

Vaxcyte Reports Second Quarter 2023 Financial Results and

-- Advanced Ongoing VAX-24 Phase 2 Infant Study to Second Stage, Dosing First New Participants in July 2023; Topline Data from Primary Immunization Series...

Eplontersen continued to show improvement in ATTRv-PN through 85 weeks - Vimarsana News

Eplontersen continued to show improvement in ATTRv-PN through 85 weeks

Topline Phase 3 NEURO-TTRansform results show eplontersen continued to halt neuropathy disease progression and improve quality of life through 85 weeksData further strengthen eplontersen's...

Vaxcyte Reports First Quarter 2023 Financial Results and Provides Business Update - Vimarsana News

Vaxcyte Reports First Quarter 2023 Financial Results and Provides Business Update

08.05.2023 - - Positive Data from VAX-24 Phase 2 Study in Adults Aged 65 and Older Demonstrated Robust Immune Responses Across all 24 Serotypes (ST) at all Doses, Confirming Prior Phase 2 Results in Adults Aged 50-64 - - Full Six-Month Safety Data from Both ...

Brii Biosciences Provides Update on Strategic Clinical Development Progress - Vimarsana News

Brii Biosciences Provides Update on Strategic Clinical Development Progress

/PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient...